Therapeutic angiogenesis for critical limb ischemia: Design of the hepatocyte growth factor therapeutic angiogenesis clinical trial

Vascular Medicine

Volumn 9, Issue 3, 2004, Pages 193-198

  Powell, Richard J ^a   Dormandy, John ^b   Simons, Michael ^a   Morishita, Ryuichi ^c   Annex, Brian H ^d,e  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b ST GEORGE S HOSPITAL   (United Kingdom)

^c OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^d Division of Cardiology   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Angiogenesis therapy; Critical limb ischemia; Gene transfer; Vascular surgery

Indexed keywords

PLACEBO; PLASMID DNA; SCATTER FACTOR; SODIUM CHLORIDE;

ADULT; ANGIOGENESIS; ARTICLE; BYPASS SURGERY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRITICAL ILLNESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; GENE THERAPY; GENE TRANSFER; HUMAN; LIMB ISCHEMIA; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PARALLEL DESIGN; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TRANSCUTANEOUS OXYGEN MONITORING;

ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HEPATOCYTE GROWTH FACTOR; HUMANS; ISCHEMIA; LOWER EXTREMITY; MALE; NEOVASCULARIZATION, PHYSIOLOGIC; PERIPHERAL VASCULAR DISEASES; RANDOMIZED CONTROLLED TRIALS; REGIONAL BLOOD FLOW; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 12344253201     PISSN: 1358863X     EISSN: None     Source Type: Journal    
DOI: 10.1191/1358863x04vm557oa     Document Type: Article

References (26)

1. Dormandy J, Heeck L, Vig S. The fate of patients with critical leg ischemia. Semin Vasc Surg 1999; 12: 142-47.
2. O'Sullivan GJ, Ray SA, Lewis JS et al. A review of alternative approaches in the management of iatrogenic femoral pseudoaneurysms. Ann R Coll Surg Engl 1999; 81: 226- 34.
3. Halperin JL. Evaluation of patients with peripheral vascular disease. Thromb Res 2002; 106: V303-11.
4. Vale PR, Isner JM, Rosenfield K. Therapeutic angiogenesis in critical limb and myocardial ischemia. J Interv Cardiol 2001; 14 511-28.
5. Morishita R, Nakamura S, Hayashi S et al. Therapeutic angiogenesis induced by human recombinant hepatocyte growth factor in rabbit hind limb ischemia model as cytokine supplement therapy. Hypertension 1999; 33: 1379-84.
6. Isner JM, Pieczek A, Schainfeld R et al. Clinical eviderice of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet 1996; 348: 370-74.
7. Baumgartner I, Pieczek A, Manor O et al. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 1998; 97: 1114-23.
8. Lederman RJ, Mendelsohn FO, Anderson RD et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication: The TRAFFIC study. Lancet 2002; 359: 2053-58.
9. Crystal RG. Transfer of genes to humans: early lessons and obstacles to success. Science 1995; 270: 404-10.
10. Wolff JA, Dowty ME, Jiao S et al. Expression of naked plasmids by cultured myotubes and entry of plasmids into T tubules and caveolae of mammalian skeletal muscle. J Cell Sci 1992; 103 (Pt 4): 1249-59.
11. Wolff JA, Malone RW, Williams P et al. Direct gene transfer into mouse muscle in vivo. Science 1990; 247: 1465-68.
12. Taniyama Y, Morishita R, Aoki M et al. Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat and rabbit hindlimb ischemia models: preclinical study for treatment a peripheral arterial disease. Gene Ther 2001; 8: 181-89.
13. Tsuboniwa N, Morishita, R, Hirano T et al. Safety evaluation of hemagglutinating virus of Japan - artificial viral envelope liposomes in nonhuman primates. Hum Gene Ther 2001; 12: 469-87.
14. Rajagopalan S, Mohler ER 3rd, Lederman RJ et al. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation 2003; 108: 1933-38.
15. Labs KH, Dormandy JA, Jaeger KA, Stuerzebecher CS, Hiatt WR. Transatlantic Conference on Clinical Trial Guidelines in Peripheral Arterial Disease: clinical trial methodology. Basel PAD Clinical Trial Methodology Group. Circulation 1999; 100: e75-81.
16. Nakamura Y, Morishita R, Higaki J et al. Hepatocyte growth factor is a novel member of the endothelium-specific growth factors: additive stimulatory effect of hepatocyte growth factor with basic fibroblast growth factor but not with vascular endothelial growth factor. J Hypertens 1996; 14: 1067-72.
17. Rajagopalan S, Trachtenberg J, Mohler E et al. Phase I study of direct administration of a replication deficient adenovirus vector containing the vascular endothelial growth factor cDNA (CI-1023) to patients with claudication. Am J Cardiol 2002; 90: 512-16.
18. Rutherford RB, Becker GJ. Standards for evaluating and reporting the results of surgical and percutaneous therapy for peripheral arterial disease. J Vasc Interv Radiol 1991; 2: 169-74.
19. Taniyama Y, Morishita R, Nakagami H et al. Potential contribution of a novel antifibrotic factor, hepatocyte growth factor, to prevention of myocardial fibrosis by angiotensin II blockade in cardiomyopathic hamsters. Circulation 2000; 102: 246-52.
20. Bussolino F, Di Renzo MF, Ziche M et al. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol 1992; 119: 629-41.
21. Comerota AJ, Throm RC, Miller KA et al. Naked plasmid DNA encoding fibroblast growth factor type 1 for the treatment of end-stage unreconstructible lower extremity ischemia: preliminary results of a phase I trial. J Vasc Surg 2002; 35: 930-36.
22. Tateishi-Yuyama E, Matsubara H, Murohara T et al. Therapeutic angiogensis for patients with limb ischemia by autologous transplantation of bone-marrow cells: a pilot study and a randomized controlled trial. Lancet 2002; 360: 427-35.
23. Nakamura T, Nawa K, Ichihara A. Partial purification and characterization of hepatocyte growth factor from serum of hepatectomized rats. Biochem Biophys Res Commun 1984; 122: 1450-59.
24. Matsumoto K, Nakamura T. Emerging multipotent aspects of hepatocyte growth factor. J Biochem (Tokyo) 1996; 119: 591-600.
25. Matsumoto K, Nakamura T. Hepatocyte growth factor (HGF) as a tissue organizer for organogenesis and regeneration. Biochem Biophys Res Commun 1997; 239: 639-44.
26. Folkman J. Clinical applications of research on angiogenesis. N Engl J Med 1995; 333: 1757-63.